Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection

Department of Infectious Diseases, University of Brescia, Italy.
Hepatology (Impact Factor: 11.06). 11/1992; 16(4):877-81.
Source: PubMed


Hepatitis C virus RNA, anti-hepatitis C virus immune response and biochemical markers of liver injury were investigated in 17 patients with acute non-A, non-B hepatitis. At the first observation, 1 to 3 wk from the clinical onset, all patients had hepatitis C virus RNA in their serum, and most (15 of 17) were positive for second-generation anti-hepatitis C virus enzyme immunoassay. Follow-up serum samples were available for 10 patients. The rate of recombinant immunoblot assay-confirmed anti-hepatitis C virus enzyme immunoassay reactivities increased from 67% in the first 3 wk to 86% after 21 wk. Elevated ALT levels were associated with hepatitis C virus RNA positivity in most of cases, but the viral nucleic acid was also detected in sera with normal or slightly increased enzyme values. None of the single antibodies tested were related to hepatitis C virus RNA positivity or to the clinical phase of the infection. Therefore hepatitis C virus RNA determination might provide important additional information as compared with anti-hepatitis C virus markers, allowing earlier diagnosis, discrimination of active infection and, possibly, prognostic evaluation.

3 Reads
  • Source
    • "RNA was extracted from liver tissue or from serum using RNAzol B (Tel-Test, Friendswood, TX). One hundred nanograms of total liver RNA or RNA extracted from 200 ml of serum were analysed by reverse transcription-nested PCR with primers located in the 5 0 untranslated region (UTR) of HCV genome, as previously described [Puoti et al., 1992]. Negative controls for the extraction, reverse transcription, and amplification steps were processed together with clinical samples, and known HCV RNA-positive samples were used as positive controls. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Few data are available on the levels of HBV DNA in liver tissue of patients with hepatocellular carcinoma. In this study, HBV DNA was quantitated by a TaqMan real-time PCR method and results were normalised to an endogenous reference gene. The assay could detect reproducibly viral sequences from over 10(7) to less than 50 copies/microg of liver DNA. The HBV DNA content in liver samples from 11 HBsAg-positive patients (median: 10(5) copies/microg of DNA) was significantly higher (P < 0.001) compared to the viral DNA concentration detected in liver samples from 15 of 25 HBsAg-negative patients (median: 2.6 x 10(2) copies/microg). A liver DNA amount > or =1 HBV DNA copy per cell was detected in half of tissue samples from HBsAg-positive patients, and in none from HBsAg-negative ones. Liver tissue HBV DNA content was significantly higher in anti-HCV-negative than in anti-HCV-positive cases (P < 0.001). These results show that the quantitation of liver HBV DNA by real-time PCR can be useful to understand HBV state in hepatocellular carcinoma and viral interplay in patients with multiple viral infections.
    Journal of Medical Virology 12/2002; 68(4):494-9. DOI:10.1002/jmv.10243 · 2.35 Impact Factor
  • Source
    • "the PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining. The specificity of the amplified fragments was further confirmed by a nonradioactive hybridization assay (DNA Enzyme Immunoassay, GEN-ETI-K DEIA, Sorin Biomedica, Saluggia, I) as described previously (Puoti et al., 1992). The DEIA relies on an anti-double stranded DNA monoclonal antibody capable of revealing the hybridization event. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HCV-RNA was examined in serum and liver tissue obtained from 8 hepatitis B surface antigen (HBsAg) negative patients with liver nodules ranging in size from 2 to 11 cm. Histological examination of ultrasound-guided fine needle biopsies revealed the presence of hepatocellular carcinoma (HCC) in six patients (5 of whom were anti-HCV positive), cholangiocarcinoma in 1 patient (anti-HCV positive) and dysplastic regenerative nodule in 1 patient (anti-HCV negative). The HCCs were surrounded by cirrhosis (3 cases), chronic active hepatitis (CAH) (n = 2) and post hepatitic fibrosis (n = 1), the cholangiocarcinoma by CAH and the regenerative nodule by cirrhotic liver. Total and replicative intermediate HCV-RNA was analyzed by reverse-transcription-nested PCR of the 5'-untranslated region. The five patients with HCC had HCV-RNA in serum, in tumorous and surrounding liver tissues. The viral nucleic acid was also detected in the cirrhotic tissue surrounding the cholangiocarcinoma but not in the tumor. Two out of 5 HCC patients had replicative intermediate RNA (negative strand) in tumorous tissue, 4 in nontumorous tissue and 3 in serum. These results demonstrate that fine needle biopsy can provide sufficient material for both histological examination and HCV-RNA determination and suggest the existence of continuous viral replication during the carcinogenic process.
    Journal of Virological Methods 08/1994; 48(2-3):125-32. DOI:10.1016/0166-0934(94)90112-0 · 1.78 Impact Factor
  • Source

Show more